Cargando…

Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study

BACKGROUND: We aimed to compare indicators of Parkinson disease (PD) progression between patients first prescribed either selegiline or rasagiline as their antiparkinsonian drugs (APDs) on the basis of real-life data. METHODS: Pharmacy data on members of a large Israeli health maintenance organizati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peretz, Chava, Segev, Hagar, Rozani, Violet, Gurevich, Tanya, El-Ad, Baruch, Tsamir, Judith, Giladi, Nir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028154/ https://www.ncbi.nlm.nih.gov/pubmed/27438181 http://dx.doi.org/10.1097/WNF.0000000000000167

Ejemplares similares

Statin adherence and the risk of Parkinson's disease: A population-based cohort study
por: Rozani, Violetta, et al.
Publicado: (2017)

Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline
por: Harsing, Laszlo G., et al.
Publicado: (2023)

Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case–control study
por: Cereda, Emanuele, et al.
Publicado: (2017)

Erratum to: Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case–control study
por: Cereda, Emanuele, et al.
Publicado: (2017)

Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies
por: Naoi, Makoto, et al.
Publicado: (2022)

Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson’s Disease: A Post Hoc Analysis
por: Giladi, Nir, et al.
Publicado: (2016)

Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro
por: Dimpfel, W, et al.
Publicado: (2011)

Effect of Rivastigmine on Mobility of Patients with Higher-Level Gait Disorder: A Pilot Exploratory Study
por: Gurevich, Tanya, et al.
Publicado: (2014)

Rasagiline in treatment of Parkinson’s disease
por: Nayak, Lakshmi, et al.
Publicado: (2008)

P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease
por: Hauser, Robert A., et al.
Publicado: (2022)

The role of rasagiline in the treatment of Parkinson’s disease
por: Leegwater-Kim, Julie, et al.
Publicado: (2010)

Rasagiline Withdrawal Syndrome in Parkinson’s Disease
por: Solla, Paolo, et al.
Publicado: (2022)

Hydride Abstraction as the Rate-Limiting Step of the Irreversible Inhibition of Monoamine Oxidase B by Rasagiline and Selegiline: A Computational Empirical Valence Bond Study
por: Tandarić, Tana, et al.
Publicado: (2020)

Adjunctive therapy in Parkinson’s disease: the role of rasagiline
por: Gaines, Kathryn D, et al.
Publicado: (2012)

Selegiline reduces daytime sleepiness in patients with Parkinson's disease
por: Gallazzi, Marco, et al.
Publicado: (2021)

Disorders of the Oral Cavity in Parkinson's Disease and Parkinsonian Syndromes
por: Zlotnik, Yair, et al.
Publicado: (2015)

Effect of gait speed on gait rhythmicity in Parkinson's disease: variability of stride time and swing time respond differently
por: Frenkel-Toledo, Silvi, et al.
Publicado: (2005)

Decreased expression of B cell related genes in leukocytes of women with Parkinson's disease
por: Kedmi, Merav, et al.
Publicado: (2011)

From a Parkinson's disease expert: Rasagiline and the Future of Therapy
por: Lakhan, Shaheen E
Publicado: (2007)

Role of rasagiline in treating Parkinson’s disease: Effect on disease progression
por: Malaty, Irene A, et al.
Publicado: (2009)

Curcumin modulation of L-dopa and rasagiline-induced neuroprotection in rotenone model of Parkinson’s disease
por: El-Shamarka, Marwa El-Sayed, et al.
Publicado: (2023)

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy
por: Lecht, Shimon, et al.
Publicado: (2007)

Rasagiline and Rapid Symptomatic Motor Effect in Parkinson’s Disease: Review of Literature
por: Pistacchi, Michele, et al.
Publicado: (2013)

Subthalamic Neurons Encode Both Single- and Multi-Limb Movements in Parkinson’s Disease Patients
por: Tankus, Ariel, et al.
Publicado: (2017)

Selegiline: a molecule with innovative potential
por: Tábi, Tamás, et al.
Publicado: (2019)

A single-center real-life study on the use of medical cannabis in patients with dystonia
por: Anis, Saar, et al.
Publicado: (2023)

Selegiline improves excessive daytime sleepiness in Parkinson's disease: an open-label observational study
por: Zhang, Jinru, et al.
Publicado: (2022)

Efficacy and safety of selegiline for the treatment of Parkinson's disease: A systematic review and meta-analysis
por: Wang, Ke, et al.
Publicado: (2023)

Rasagiline Ameliorates Olfactory Deficits in an Alpha-Synuclein Mouse Model of Parkinson's Disease
por: Petit, Géraldine H., et al.
Publicado: (2013)

Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study
por: Schettino, Carla, et al.
Publicado: (2016)

Rasagiline, sleep quality and well-being in Parkinson’s disease: a pilot study
por: Mutti, Carlotta, et al.
Publicado: (2022)

White Matter Hyperintensities in Parkinson’s Disease: Do They Explain the Disparity between the Postural Instability Gait Difficulty and Tremor Dominant Subtypes?
por: Herman, Talia, et al.
Publicado: (2013)

Transdermal selegiline for the treatment of major depressive disorder
por: Lee, Kelly C, et al.
Publicado: (2007)

Effects on Sperms’ Quality of Selegiline in Aged Rats
por: Kalász, Huba, et al.
Publicado: (2017)

Rasagiline does not exacerbate autonomic blood pressure dysregulation in early or mild Parkinson’s disease
por: Oka, Hisayoshi, et al.
Publicado: (2021)

Rasagiline as Adjunct to Levodopa for Treatment of Parkinson's Disease: A Systematic Review and Meta-Analysis
por: Kano, Osamu, et al.
Publicado: (2022)

No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson's disease mice
por: Zheng, Cheng-you, et al.
Publicado: (2016)

Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

Linezolid and Rasagiline – A culprit for serotonin syndrome
por: Hisham, Mohamed, et al.
Publicado: (2016)

Accumulation of (123)I-Ioflupane Is a Useful Marker of the Efficacy of Selegiline Monotherapy in Drug-Naïve Parkinson’s Disease
por: Murakami, Hidetomo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jc2713f59ditl550glj2s9u3ac